ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 74

IL-17 Blockade Attenuates Osteoblastic Activity and Differentiation in Ankylosing Spondylitis

Sungsin Jo1, Ye-Soo Park2, Il-Hoon Sung3 and Tae-Hwan Kim1, 1Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), 2Orthopaedic, Hanyang University Guri Hospital, Guri, Korea, Republic of (South), 3Orthopaedic, Hanyang University Seoul Hospital, Seoul, Korea, Republic of (South)

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Ankylosing spondylitis (AS), interleukins (IL) and osteoblasts

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis Poster I: The Variable World of Intercellular Signalling

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Ankylosing spondylitis (AS) is a chronic inflammatory bone disease mediated by proinflammatory cytokine secreted by specialized T cells population. The mechanism by which the development of and function of Th17 cells and emerging IL-23/IL-17 axis may be involved in the pathogenesis of AS. However, the effect of IL-17 and IL-23 in osteoblast remain to be elucidated.

Methods:

AS patients satisfying the modified New York criteria were recruited for the study. Healthy donor, rheumatoid arthritis patients and osteoarthritis patients were included as controls. TNFa, IL-17, and IL-23 level were quantized by ELISA in the serum and synovial fluid. Bone tissues were obtained at surgery from facet joints of 10 patient with AS and 26 patients with noninflammatory spinal disease from traffic trauma or spinal compression disease, who served as controls. Immunohistochemistry and RNA level of bone tissue and isolated primary osteoprogenitor cells were performed to identify dominant JAK2 expression. IL-17 cytokine or patient serum with AS stimulated primary osteoprogenitor cells was analyzed by intercellular alkaline phosphatase (ALP) activity, mineralization, real-time PCR, and immunoblotting.

Results:

IL-17 and IL-23 basal level were significantly elevated in serum and synovial fluid of AS patients compared to those of the controls. Expression of JAK2 was enriched in bone tissues and isolated primary osteoprogenitor cells of AS patient. An addition of IL-17 cytokine in osteogenic differentiation exhibited an increase in ALP activity and calcium deposit in cellular level and sustained phos-JAK2 and phos-STAT3, and C/EBPβ in molecular level. Furthermore, adding IL-17A blockade in presence of patient serum with AS upon differentiation exhibited reduced intercellular ALP activity, mineralization, and phos-JAK2 expression in both control and AS osteoprogenitor cells. Intriguing, AG490, a JAK2 specific inhibitor, suppressed ALP activity despite the presence of patient serum with AS.

Conclusion:

This study supports a role of IL-17A in the pathogenesis of AS and attempts to provide a link between proinflammatory cytokine and osteoblast activity in an unexplored cellular system. Blocking of IL-17 could attenuate bony ankyloses in AS.


Disclosure: S. Jo, None; Y. S. Park, None; I. H. Sung, None; T. H. Kim, None.

To cite this abstract in AMA style:

Jo S, Park YS, Sung IH, Kim TH. IL-17 Blockade Attenuates Osteoblastic Activity and Differentiation in Ankylosing Spondylitis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/il-17-blockade-attenuates-osteoblastic-activity-and-differentiation-in-ankylosing-spondylitis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/il-17-blockade-attenuates-osteoblastic-activity-and-differentiation-in-ankylosing-spondylitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology